Ozempic vs Wegovy: same drug, two labels, two dose ceilings

Here is the single most useful fact about Ozempic and Wegovy: they are the same drug. Both are semaglutide, both are made by Novo Nordisk, and both are the same once-weekly injectable GLP-1 receptor agonist. What differs is the label — the FDA-approved use each brand is sold under, and the maximum dose each is approved to reach. Ozempic is approved for type 2 diabetes; Wegovy is approved for chronic weight management. Understanding that distinction explains almost everything that confuses people about these two names, including why insurance treats them so differently.

Same molecule, two brands

Ozempic and Wegovy both deliver semaglutide, a GLP-1 receptor agonist that slows gastric emptying, increases satiety, and improves glucose handling. There is no pharmacological difference in the active ingredient between the two. The reason there are two names is regulatory and commercial: Novo Nordisk ran separate development programs and obtained separate FDA approvals for two distinct purposes, and the brands are dosed and marketed for those purposes. So the everyday framing of “Ozempic vs Wegovy” is slightly misleading — it is one molecule wearing two labels, not two competing drugs.

Different FDA-approved use

Ozempic is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, with a maximum approved dose of 2.0 mg once weekly.^[4] Wegovy is approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults and adolescents who meet the BMI criteria, at a maximum dose of 2.4 mg once weekly.^[5] The indications are what separate them on paper: Ozempic’s on-label job is blood sugar; Wegovy’s on-label job is weight. Weight loss is a documented effect of semaglutide in both settings, but only Wegovy carries the FDA indication for it.

Different dose ladders

Both brands start low and titrate up over weeks to limit gastrointestinal side effects, but they top out at different ceilings. Ozempic’s ladder is capped at 2.0 mg.^[4] Wegovy climbs one rung higher, to 2.4 mg.^[5] That extra increment matters because the largest weight-loss results were generated at the higher 2.4 mg dose. The titration schedules are deliberately gradual in both cases — stepping up too quickly is the main driver of the nausea, vomiting and constipation that lead people to stop.

What the trials actually showed

For weight specifically, the headline data come from the STEP program at the Wegovy dose. In STEP 1, adults with overweight or obesity but without diabetes lost roughly 15% of body weight on semaglutide 2.4 mg over 68 weeks, versus about 2.4% on placebo — a large, well-powered result.^[1] A head-to-head trial, STEP 8, compared semaglutide 2.4 mg against daily liraglutide 3.0 mg and found semaglutide produced significantly greater weight loss.^[2] On the diabetes side, the SUSTAIN program established semaglutide’s glucose-lowering efficacy; SUSTAIN 7 showed once-weekly semaglutide outperformed dulaglutide on both HbA1c and body weight in type 2 diabetes,^[3] and SUSTAIN-6 demonstrated a cardiovascular benefit in higher-risk patients with type 2 diabetes.^[6] The practical read: the drug works for weight at the 2.4 mg dose Wegovy reaches, and it works for glucose at the doses Ozempic reaches — same molecule, different endpoints studied. The full semaglutide weight-loss trial record goes deeper on the numbers.

Why insurance covers them differently

Because the indications differ, coverage differs. Plans that cover Ozempic do so under a type 2 diabetes diagnosis; coverage for Wegovy depends on whether a given plan covers anti-obesity medications at all, which many historically have not. That gap — not any difference in the chemistry — is why some people are prescribed Ozempic “off-label” for weight, or why the two brands can carry very different out-of-pocket costs. Prescribing the diabetes brand for weight loss raises its own access and ethical questions, and it is worth understanding the coverage mechanics before assuming one brand is simply “cheaper.” Our breakdown of GLP-1 cost and insurance coverage covers how these decisions actually play out.

The practical takeaway

Ozempic and Wegovy are the same active drug at different approved doses for different approved uses. If the goal is glycemic control in type 2 diabetes, Ozempic is the on-label tool; if the goal is chronic weight management, Wegovy is the on-label tool and reaches the higher 2.4 mg dose that the large weight trials used. Choosing between them is really a conversation about diagnosis, dose ceiling and coverage with a prescriber — not a contest between two different medicines. And if you are weighing semaglutide against the other leading GLP-1, the tirzepatide vs semaglutide evidence is the more meaningful comparison than Ozempic vs Wegovy.